EyePoint Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021

Rhea-AI Summary

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) will hold a conference call on March 4, 2021, at 8:30 a.m. ET to discuss its full year 2020 financial results and recent business highlights. The call can be accessed by dialing (877)-312-7507 or (631)-813-4828 with conference ID 1261618. The company focuses on developing therapeutics for serious eye disorders, leveraging Durasert® technology for sustained drug delivery. EyePoint has two commercial products: YUTIQ® and DEXYCU®.

Positive

• Company is hosting a conference call to discuss full year 2020 financial results, signaling transparency and communication with investors.
• Focus on innovative therapeutics for serious eye disorders indicates potential for future growth.
• Two commercial products currently available may provide steady revenue streams.

Negative

• Details regarding financial performance for 2020 are not provided, leading to uncertainty about revenue and earnings.
• -

WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 4, 2021 to report its full year 2020 financial results and discuss recent business highlights.

To access the live conference call, please dial (877)-312-7507 (domestic) or (631)-813-4828 (international) and reference conference ID 1261618. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.

Investors:

Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com

Media Contact

Tom Gibson
GIBSON Communications, LLC
Direct: (201) 476-0322
tom@tomgibsoncommunications.com

FAQ

When is EyePoint Pharmaceuticals' conference call to discuss financial results?

EyePoint Pharmaceuticals' conference call is scheduled for March 4, 2021, at 8:30 a.m. ET.

What products does EyePoint Pharmaceuticals currently have on the market?

EyePoint Pharmaceuticals has two commercial products: YUTIQ® and DEXYCU®.

What is the focus of EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals is focused on developing therapeutics for serious eye disorders using its proprietary Durasert® technology.

How can I access the live webcast of EyePoint Pharmaceuticals' conference call?

The live audio webcast can be accessed via the Investors section of EyePoint Pharmaceuticals' website.